Physician profile
Jeffrey Smith
NPI 1932147188
$8,523.95
in general payments reported to CMS, 2019-2025
29 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $525 · 2021: $893 · 2022: $1,105 · 2023: $1,712 · 2024: $2,187 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,592.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,190.21 | 2019-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,097.23 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $838.94 | 2019-2025 | Trintellix |
| Abbvie INC. | $790.77 | 2021-2025 | Vraylar |
| Lundbeck LLC | $777.79 | 2019-2025 | Rexulti |
| Tris Pharma INC | $459.37 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $384.98 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $341.10 | 2021-2024 | Azstarys |
| Bausch Health US, LLC | $294.37 | 2020-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $290.13 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Alkermes, INC. | $285.37 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $276.07 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $224.94 | 2022-2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $224.63 | 2019-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $159.27 | 2021-2024 | Jornay Pm |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $143.65 | 2020-2022 | |
| Noven Therapeutics, LLC | $123.51 | 2024-2025 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $96.69 | 2021-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $82.36 | 2019-2021 | |
| Almatica Pharma LLC | $70.08 | 2023 | Loreev Xr, Sertraline Hcl |
| Allergan, INC. | $63.96 | 2020 | |
| Idorsia Pharmaceuticals US INC | $61.65 | 2022-2024 | Quviviq |
| Adlon Therapeutics L.P. | $47.96 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $46.36 | 2025 | |
| Harmony Biosciences LLC | $42.52 | 2023-2025 | Wakix |
| Tonix Medicines, INC. | $39.51 | 2025 | Tonmya |
| Arbor Pharmaceuticals, INC. | $29.28 | 2019-2020 | |
| Shire North American Group INC | $25.91 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.34 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.